OCA
TRML

Octagon Capital Advisors’s Tourmaline Bio TRML Stock Holding History

Octagon Capital Advisors’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-905,000
Closed -$14.5M – 31
2025
Q2 		$14.5M Hold
905,000
– – 3.18% 14
2025
Q1 		$13.8M Buy
+905,000
New +$14.5M 2.66% 15

Other funds holding TRML

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Octagon Capital Advisors's TRML Position: Q3 2025 in Review

Octagon Capital Advisors sold out of Tourmaline Bio (TRML) in Q3 2025, closing a stake of 905,000 shares — an estimated $14.5M sold.

Octagon Capital Advisors first reported a position in TRML in Q1 2025 and held it in 2 quarters. The position peaked at $14.5M in Q2 2025. 134 funds tracked by Wall St. Rank hold TRML as of Q3 2025.

  • Octagon Capital Advisors reported no remaining Tourmaline Bio position as of Q3 2025 after selling out during the quarter.
  • Octagon Capital Advisors sold 905,000 Tourmaline Bio shares in Q3 2025, an estimated $14.5M.
  • Octagon Capital Advisors first reported a position in Tourmaline Bio in Q1 2025 and held it in 2 quarters.
  • Octagon Capital Advisors's Tourmaline Bio position peaked at $14.5M in Q2 2025.
  • 134 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2025.

Based on Octagon Capital Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.